Completed

Effect of Sarpogrelate On the Nephropathy in Type 2 Diabetes

What is being tested

Anplag(Sarpogrelate)

+ Placebo

Drug

Who is being recruted

Urogenital Diseases+7

+ Diabetes Mellitus

+ Diabetic Nephropathies

Over 20 Years

+11 Eligibility Criteria

See all eligibility criteria

How is the trial designed

Treatment Study

Placebo-ControlledPhase 4

Interventional

Study Start: February 2013

See protocol details

Summary

Principal SponsorYuhan Corporation

Last updated: January 28, 2026

Sourced from a government-validated database.Claim as a partner

Study start date: February 1, 2013

Actual date on which the first participant was enrolled.

Phase 4 Study to evaluate the safety and effect on decreasing subjects' albuminuria who have Type 2 Diabetes by using sarpogrelate and placebo.

Official TitleEffect of Sarpogrelate On the Nephropathy in Type 2 Diabetes

NCT01869881

Principal SponsorYuhan Corporation

Last updated: January 28, 2026

Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.

Design Details

151 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Treatment Study

These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.

Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.

Conditions

Criteria

Any sex

Biological sex of participants that are eligible to enroll.

Over 20 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Urogenital DiseasesDiabetes MellitusDiabetic NephropathiesEndocrine System DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsKidney DiseasesUrologic DiseasesDiabetes ComplicationsFemale Urogenital DiseasesMale Urogenital Diseases

Criteria

3 inclusion criteria required to participate

person who signed on ICF

Type 2 diabetic patient who have microalbuminuria or overt proteinuria

In case of hypertension patients, who keep the same medication steadily over last 4 weeks

8 exclusion criteria prevent from participating

patients who have hypersensitivity on sarpogrelate or other salicylic acid

patients who should keep the antiplatelet agent because of acute cardiac disease or peripheral vein disease

patients who took other anticoagulant agent within 1 month

patient who take ACEI OR ARB but not controlled(over 150/100mmHg)

Show More Criteria

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.

Treatment Groups

Study Objectives

2 intervention groups are designated in this study

50% chance of being blinded to the placebo group

Treatment Groups

Group I

Active Comparator

Group II

Placebo

Study Objectives

Primary Objectives

Secondary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 1 location

Suspended

Korea University, Anam

Seoul, South KoreaOpen Korea University, Anam in Google Maps

CompletedOne Study Center